H. Ward Wolff

Mr. H. Ward Wolff has served as a member of the board of directors since December 2014. Mr. Wolff served as Executive Vice President and Chief Financial Officer of Sangamo Therapeutics from December 2007 until his retirement in March 2017. Prior to Sangamo, Mr. Wolff was with Nuvelo, where he served as Senior Vice President, Finance, and Chief Financial Officer until its restructuring in August 2007. Prior to that, he was Chief Financial Officer and Senior Vice President, Finance, of Abgenix until April 2006 when Abgenix merged with Amgen. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including serving as Senior Vice President and CFO of DoubleTwist. He began his career with Price Waterhouse, where he held a number of positions as a certified public accountant, including senior audit manager. Mr. Wolff was a member of the board of directors of Sunesis Pharmaceuticals until its merger with Viracta in February 2021 and Portola Pharmaceuticals until its merger with Alexion Pharmaceuticals in July 2020. From June 2006 until his appointment to Sangamo’s management team he was a member of Sangamo’s Board of Directors, serving as Chairman of the audit committee. Mr. Wolff received a B.A. degree in Economics from the University of California at Berkeley, and an M.B.A. degree from Harvard Business School.